Title : The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.

Pub. Date : 2013 Mar 1

PMID : 23234544






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Finally, cancer cells in which acquired resistance to selumetinib arises through BRAF(V600E) amplification remained sensitive to ABT-263, whereas selumetinib-resistant HCT116 cells (KRAS(G13D) amplification) were cross-resistant to ABT-263. AZD 6244 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens